Form 4: Halozyme CEO Exercises, Sells 60,000 Shares

Halozyme Therapeutics' President and CEO, Helen Torley, exercised and immediately sold 60,000 shares of common stock over three days in November 2025, pursuant to a Rule 10b5-1 trading plan.

Summary

• Helen Torley, President and CEO, and a Director of Halozyme Therapeutics, Inc. (HALO), engaged in a series of transactions involving the company's common stock.
• Over three days (November 10-12, 2025), Torley exercised options to acquire a total of 60,000 shares of common stock at an exercise price of $8.11 per share.
• Concurrently, she sold all 60,000 newly acquired shares in multiple transactions at weighted average prices ranging from $67.892 to $71.667 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2025.
• The shares sold were acquired from stock options granted on February 3, 2016, which had a ten-year term expiring in February 2026.
• Following these transactions, Torley's direct beneficial ownership of common stock remained at 733,719 shares, while her beneficial ownership of derivative options decreased by 60,000 to 16,569 options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an executive selling shares can sometimes be seen negatively, these sales were pre-planned under a 10b5-1 plan and involved exercising expiring options, indicating a routine liquidity event rather than a lack of confidence. The significant profit margin on the options reflects positively on the company's stock performance over the option's life.

Positives

• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned and not reactive sale.
• The significant difference between the option exercise price ($8.11) and the sale prices (ranging from $67.892 to $71.667) indicates substantial personal gain for the executive, reflecting the company's stock appreciation over the option's life.

Negatives

• The CEO sold a substantial number of shares (60,000), which could be perceived as a reduction in her direct equity exposure, although it was offset by option exercises.
• The sale represents a monetization of long-held options, which is a common practice but still reduces the executive's direct stake in the company's future stock price movements for those specific shares.

Future Outlook

This Form 4 filing is a report of past insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports routine insider transactions under a pre-arranged trading plan, which is a common practice for executives to manage their equity holdings and liquidity. It does not provide specific insights into broader industry trends or competitive positioning, but rather reflects an individual executive's financial planning within the context of their compensation.

Stakeholder Impact

• Shareholders: The sale of shares by a high-ranking executive, even if pre-planned, could be interpreted differently by investors. However, the net zero change in common stock ownership (due to simultaneous exercise and sale) and the significant profit realized by the executive might be viewed positively as a reward for long-term performance.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• No specific future actions or milestones for the company are mentioned in this insider transaction report. The reporting person's remaining options will expire on February 3, 2026.

Key Dates

Recommendation

This Form 4 reports routine insider transactions by the CEO, involving the exercise of expiring stock options and the immediate sale of the acquired shares under a pre-arranged 10b5-1 plan. While the executive monetized a significant portion of her options, the net effect on her direct common stock holdings was neutral for these specific transactions. The substantial profit realized reflects past stock appreciation, which is positive. However, the filing itself does not provide new information about the company's operational performance, strategic direction, or future prospects that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on existing company fundamentals and market outlook, as this filing does not introduce new factors for a 'buy' or 'sell' decision.

Keywords

Halozyme Therapeutics, HALO, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Executive Compensation, Helen Torley, Share Sale, Option Exercise